Optimum bioconjugated cytokines selectively enhanced their therapeutic potency and reduces side-effects.

最佳的生物共轭细胞因子选择性地增强其治疗效力并减少副作用。

基本信息

  • 批准号:
    09470512
  • 负责人:
  • 金额:
    $ 7.23万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1998
  • 项目状态:
    已结题

项目摘要

The in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6. Native IL-6 and MPEG-IL-6, which showed about 51 % of the specific bioactivity of native IL-6, were administered subcutaneously to mice every 2 days for 7 days. Native IL-6 increased not only the peripheral platelet count, but also the plasma-IgG1 level in a dose-dependent manner. MPEG-IL-6 showed about 500 times higher thrombopojetic potency than native IL-6. Further, in comparison to native IL-6, MPEG-IL-6 did not enhance IgG1 production as much as it enhanced platelet production. MPEG-IL-6 significantly stimulated platelet recovery in mice treated with 5-fluorouracil, whereas the administration of native IL-6 had a negligible effect. The plasma half-life of MPEG-IL-6 was about 100-fold longer than that of native IL-6. The decrease in the plasma clearance of MPEG-IL-6 was thought to be due, in part, to the shielding of the proteolytic sites in the IL-6 molecule by the PEG chain. The uptake of IL-6 by the reticuloendothelial system, such as the liver and spleen, was markedly limited by PEGylation. The PEGylation of IL-6 markedly enhanced the blood-residency of IL-6, resulting in effective augmentation of its thrombopoietic activity and a marked decrease in its side-effects. These findings suggest that MPEG-IL-6 may be a potential candidate for thrombopoietic agent.
将聚乙二醇修饰的白细胞介素-6(MPEG-IL-6)(其中IL-6的14个赖氨酸氨基中的54%与PEG偶联)的体内血小板生成活性与天然IL-6的体内血小板生成活性进行比较。将天然IL-6和MPEG-IL-6(其显示天然IL-6的约51%的比生物活性)每2天皮下施用至小鼠,持续7天。天然IL-6不仅增加外周血小板计数,而且以剂量依赖性方式增加血浆IgG 1水平。MPEG-IL-6显示出比天然IL-6高约500倍的促血小板生成效力。此外,与天然IL-6相比,MPEG-IL-6并不像其增强血小板产生那样增强IgG 1产生。MPEG-IL-6显著刺激用5-氟尿嘧啶处理的小鼠的血小板恢复,而施用天然IL-6具有可忽略的作用。MPEG-IL-6的血浆半衰期比天然IL-6的血浆半衰期长约100倍。MPEG-IL-6的血浆清除率降低被认为部分是由于PEG链屏蔽了IL-6分子中的蛋白水解位点。网状内皮系统(如肝脏和脾脏)对IL-6的摄取明显受到PEG化的限制。IL-6的PEG化修饰显著增强了IL-6的血液驻留,从而有效地增强了其血小板生成活性并显著降低了其副作用。这些结果表明,MPEG-IL-6可能是一个潜在的候选血小板生成剂。

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mayumi T.et al.: "Lecithinaization of IL-6 enhances its thrombopoietic activity." J.Pharm.Pharmacol.49. 113-118 (1997)
Mayumi T.等人:“IL-6 的卵磷脂化增强了其血小板生成活性。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kaneda Y., Yamamoto Y., Kamada H., Tsunoda S., Tsutsumi Y., Hirano T., Mayumi T.: "Antitumor activity of tumor necrosis factor-alpha conjugated with diviny ether and maleic anhydride copolymer on solid tumors in mice." Cancer Res.58. 290-295 (1998)
Kaneda Y.、Yamamoto Y.、Kamada H.、Tsunoda S.、Ttsutsumi Y.、Hirano T.、Mayumi T.:“肿瘤坏死因子-α 与乙醚和马来酸酐共聚物缀合对小鼠实体瘤的抗肿瘤活性
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Mu Y., Kamada H., Kaneda Y., Yamamoto Y., Kodaira H., Tsunoda S., Tsutsumi T., Maeda M., Kawasaki K., Nomizu M., Yamada Y., and Mayumi T.: "Bioconjugation of laminin peptide YIGSR with poly (stirene co-maleic acid) increases its antimetastatic effect on l
Mu Y.、Kamada H.、Kaneda Y.、Yamamoto Y.、Kodaira H.、Tsunoda S.、Ttsutsumi T.、Maeda M.、Kawasaki K.、Nomizu M.、Yamada Y. 和 Mayumi T.:“
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tsutsumi Y.et al.: "Amino acids and peptides XXXIII. A bifunctional poly (ethylene glycol) hybrid of laminin-related peptides." Biochem.Biophy.Res.Commun.248. 485-489 (1998)
Tsutsumi Y.et al.:“氨基酸和肽 XXXIII。层粘连蛋白相关肽的双功能聚(乙二醇)杂合体。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tsutsumi Y.et al.: "Amino acids and peptides XXXIII.A bifunctional poly(ethylene glycol)hybrid of laminin-related peptides." Biochem.Biophys.Res.Commun.248. 485-489 (1998)
Tsutsumi Y.et al.:“氨基酸和肽 XXXIII.层粘连蛋白相关肽的双功能聚(乙二醇)杂化物。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MAYUMI Tadanori其他文献

MAYUMI Tadanori的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MAYUMI Tadanori', 18)}}的其他基金

Development of novel vaccine adjuvant for infectious disease
新型传染病疫苗佐剂的研制
  • 批准号:
    13557204
  • 财政年份:
    2001
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of intracellular controlled release system for optimization of gene therapy
开发细胞内控释系统以优化基因治疗
  • 批准号:
    13470515
  • 财政年份:
    2001
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Cancer gene therapy by the in vivo transfer of cytokine-genes in to the artery that leads to tumors with fusogenic liposomes.
癌症基因治疗通过将细胞因子基因体内转移到动脉中,用融合脂质体导致肿瘤。
  • 批准号:
    09557194
  • 财政年份:
    1997
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Preparation of aniti-tumor tissue endothelium antibodies and its application of cancer-missle therapy
抗肿瘤组织内皮抗体的制备及其在肿瘤导弹治疗中的应用
  • 批准号:
    07457615
  • 财政年份:
    1995
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of fusogenic liposomes which can deliver any substances into the cells through membrane fusion
开发融合脂质体,可通过膜融合将任何物质输送到细胞中
  • 批准号:
    07557312
  • 财政年份:
    1995
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

Developing a Novel Phosphorus-Based Bioconjugation Technique for Enzyme Immobilization
开发一种新型的基于磷的酶固定化生物共轭技术
  • 批准号:
    575729-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Development of Bifunctional and Light Activated ReACT Bioconjugation Reagents via Nitrone Photoisomerization
通过硝酮光异构化开发双功能光激活 ReACT 生物共轭试剂
  • 批准号:
    10389513
  • 财政年份:
    2022
  • 资助金额:
    $ 7.23万
  • 项目类别:
Development of Bifunctional and Light Activated ReACT Bioconjugation Reagents via Nitrone Photoisomerization
通过硝酮光异构化开发双功能光激活 ReACT 生物共轭试剂
  • 批准号:
    10555205
  • 财政年份:
    2022
  • 资助金额:
    $ 7.23万
  • 项目类别:
Harnessing molecular strain for drug discovery and bioconjugation
利用分子菌株进行药物发现和生物共轭
  • 批准号:
    DP210101585
  • 财政年份:
    2021
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Discovery Projects
Bioconjugation: Novel Reagents and Strategies for Cysteine and Disulfide Modification
生物共轭:半胱氨酸和二硫键修饰的新型试剂和策略
  • 批准号:
    2582933
  • 财政年份:
    2021
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Studentship
Development of a highly selective bioconjugation method using protein interactions
利用蛋白质相互作用开发高选择性生物共轭方法
  • 批准号:
    21K19331
  • 财政年份:
    2021
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Towards broad-spectrum antimicrobial vaccines: uniting automated and enzymatic glycan assembly for the synthesis and bioconjugation of bacterial exopo
迈向广谱抗菌疫苗:将自动化和酶促聚糖组装结合起来,用于细菌外泌体的合成和生物共轭
  • 批准号:
    2595945
  • 财政年份:
    2021
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Studentship
Boronic Acid Chemistry as a Modern Platform in Catalysis, Stereocontrolled Synthesis and Bioconjugation
硼酸化学作为催化、立体控制合成和生物共轭的现代平台
  • 批准号:
    RGPIN-2017-05086
  • 财政年份:
    2021
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Discovery Grants Program - Individual
Enzyme cooperativity, biocatalysis and bioconjugation
酶协同作用、生物催化和生物结合
  • 批准号:
    RGPIN-2017-04107
  • 财政年份:
    2021
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Discovery Grants Program - Individual
SBIR Phase I: Developing Bioconjugation and Preparation of 18F-Biomolecules for PET Imaging
SBIR 第一阶段:开发用于 PET 成像的 18F-生物分子的生物共轭和制备
  • 批准号:
    2124459
  • 财政年份:
    2021
  • 资助金额:
    $ 7.23万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了